COULD THIS REDUCE LOST LIVES DUE TO COV-19?
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives.
We are looking to build a portfolio of novel antimicrobial drug products that can access markets closed to traditional antibiotics due to the threat of antimicrobial resistance (AMR), generic competition and pricing challenges.
About China-UK Industrial Research programme
The new China-UK Industrial Research programme seeks to extend the knowledge base and activity profile of these novel drugs. This will include study of multi-drug resistant (MDR), It will also evaluate combining XF-drugs with existing antibiotics to synergise and/or restore their efficacy against priority antibiotic resistant bacteria.
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling antimicrobial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com